Filing Details
- Accession Number:
- 0001209191-22-005434
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-01-28 16:47:40
- Reporting Period:
- 2022-01-26
- Accepted Time:
- 2022-01-28 16:47:40
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1290149 | Sierra Oncology Inc. | SRRA | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1295674 | Christina Mary Thomson | C/O Sierra Oncology, Inc. 1820 Gateway Drive, Suite 110 San Mateo CA 94404 | General Counsel & Secretary | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2022-01-26 | 2,000 | $13.04 | 2,000 | No | 4 | M | Direct | |
Common Stock | Disposition | 2022-01-26 | 2,000 | $29.00 | 0 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy) | Acquisiton | 2022-01-26 | 2,000 | $0.00 | 2,000 | $13.04 |
Common Stock | Stock Option (Right to Buy) | Acquisiton | 2022-01-28 | 12,250 | $0.00 | 12,250 | $12.15 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | 2030-07-28 | No | 4 | M | Direct | |
12,250 | 2022-01-28 | 2030-08-12 | No | 4 | A | Direct |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 21, 2022. The Reporting Person is subject to a Lock-Up Letter Agreement that expires on April 26, 2022. The sale of shares is a permissible exemption under the terms of the Lock-Up Letter Agreement.
- On July 28, 2021, the option vested as to 25% of the total shares granted on July 28, 2020, with the remaining shares from that grant vesting in equal monthly installments over the following 36 months, with 100% of the total shares vested on July 28, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
- On August 12, 2020, the Reporting Person was granted an option to purchase 49,000 shares of common stock. The option vests based on the satisfaction by Issuer of certain performance criteria. The achievement of one of the performance criteria resulted in vesting of the option as to 12,250 shares.